Alithea Genomics closes CHF 6.9M round and names new CEO
Alithea Genomics, an EPFL spin-out based at Biopôle, raised CHF 6.9M in a seed round led by Genku Ventures with participation from Novalis Biotech and Zürcher Kantonalbank, and appointed Frederik Decouttere as CEO while cofounder Riccardo Dainese becomes CCO and Kaspar Binz assumes the chair. The company commercializes massively multiplexed BRB-seq and DRUG-seq RNA‑seq library-prep platforms that can process up to 1,536 samples per tube, aiming to cut cost and time for industrial-scale transcriptomics.
Why it mattersNaming Frederik Decouttere CEO after a CHF 6.9M raise accelerates Alithea's BRB-seq commercialization.
Entities Mentioned
Alithea GenomicsEPFLBiopôleGenku VenturesNovalis BiotechZürcher Kantonalbank
People Mentioned
Frederik DecouttereRiccardo DaineseKaspar Binzstartupticker.ch